In systemic lupus erythematosus (SLE), antiphospholipid antibodies (APA), detected either by ELISA (anticardiolipin antibodies, A C A) or by an inhibitory effect on phospholipid-dependent in vitro blood coagulation (lupus anticoagulant, LAC), are strongly associated with recurrent thrombosis, fetal loss, thrombocytopenia and neurological pathology (the """"""""antiphospholipid syndrome"""""""" APS). When acquired coagulation abnormalities of APS occur in the absence of SLE, it is referred to as primary APS. To date, the role of APA in immunopathogenesis of APS remains unclear. Analyses of APA indicate that they are composed of immunologically and functionally distinct antibody species. Considering that some individuals with persistently elevated serum ACA and LAC do not experience thrombotic problems, we hypothesize that only certain APA in APS patients may cause thrombosis, and that such thrombogenic APA is necessary, but not sufficient for, induction of pathologic thrombosis. The potentially thrombogenic antibodies may possess unique binding specificity and affinity to phospholipid and/or cofactor(s), not appreciated with present analyses of polyclonal heterogeneous APA in plasma samples. To test these hypotheses, we plan to: 1 Generate monoclonal IgG APA from APS patients with high titers of serum APA and recurrent thrombosis, and characterize the binding specificities and affinities of the monoclonal APA; 2) Determine the functional properties of monospecific APA by in vitro blood clotting assays and an in vivo thrombosis model in mice; 3) Study the mechanisms by which thrombogenic and anticoagulant APA exert their effects; The results from these studies will help to define various subsets of APA in APS patients with recurrent thrombosis, and to advance our understanding about the role of APA in thrombosis associated with APS. If some thrombogenic APA are found, their immunological characteristics and pathogenic mechanisms will be revealed.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR042506-02
Application #
2006347
Study Section
Special Emphasis Panel (ZRG4-GMA-2 (01))
Project Start
1996-02-25
Project End
1997-11-30
Budget Start
1996-12-01
Budget End
1997-11-30
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Chen, P P; Wu, M; Hahn, B H (2010) Some antiphospholipid antibodies bind to various serine proteases in hemostasis and tip the balance toward hypercoagulant states. Lupus 19:365-9
Yang, Yao-Hsu; Chien, Daniel; Wu, Meifang et al. (2009) Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. J Immunol 182:1674-80
Ede, Kaleo; Hwang, Kwan-Ki; Wu, Chen-Ching et al. (2009) Plasmin immunization preferentially induces potentially prothrombotic IgG anticardiolipin antibodies in MRL/MpJ mice. Arthritis Rheum 60:3108-17
Pierangeli, Silvia S; Chen, Pojen P; Raschi, Elena et al. (2008) Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 34:236-50
Chen, P P; Yang, C D; Ede, K et al. (2008) Some antiphospholipid antibodies bind to hemostasis and fibrinolysis proteases and promote thrombosis. Lupus 17:916-21
Lin, Wei-Shiang; Chen, Pei-Chih; Yang, Cheng-De et al. (2007) Some antiphospholipid antibodies recognize conformational epitopes shared by beta2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 56:1638-47
Chen, Xiao-Xiang; Gu, Yue-Ying; Li, Shu-Jie et al. (2007) Some plasmin-induced antibodies bind to cardiolipin, display lupus anticoagulant activity and induce fetal loss in mice. J Immunol 178:5351-6
Vega-Ostertag, Mariano; Liu, Xiaowei; Kwan-Ki, Hwang et al. (2006) A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells. Br J Haematol 135:214-9
Yang, Yao-Hsu; Hwang, Kwan-Ki; FitzGerald, John et al. (2006) Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin. J Immunol 177:8219-25
Lu, Cai-Sheng; Horizon, Arash A; Hwang, Kwan-Ki et al. (2005) Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum 52:4018-27

Showing the most recent 10 out of 21 publications